Used in treatment of tardive dyskinesia in adults
Zydus Lifesciences' subsidiary Zydus Worldwide DMCC has received tentative approval from the United States Food and Drug Administration (USFDA) to market Valbenazine Capsules USP 40 mg, 60 mg, and 80 mg (USRLD: Ingrezza).Valbenazine Capsules are indicated for the treatment of adults with tardive dyskinesia (movements in the face, tongue, or other body parts that cannot be controlled). The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
